指南与共识乳腺癌

Watson for Oncology与乳腺癌治疗推荐的一致性:与多学科肿瘤委员会的对比

Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
指南 / 共识 · Ann Oncol · 2018-01-01

该研究对比了人工智能临床决策支持系统Watson for Oncology(WFO)与多学科肿瘤委员会对2014至2016年印度Manipal综合癌症中心638例乳腺癌的治疗推荐一致性。结果显示总体一致率为93%,分期和年龄显著影响一致性,而受体状态无显著影响,提示WFO可能有助于资源有限中心的乳腺癌治疗决策。

要点

  • WFO与肿瘤委员会治疗推荐总体一致率为93%。
  • I期或IV期患者一致性低于II期或III期。
  • 年龄增长显著影响一致性,受体状态无影响。

核心结论

  • WFO与肿瘤委员会对乳腺癌病例的治疗推荐高度一致,分期和年龄显著影响一致性,受体状态无影响。

研究设计与样本

  • 回顾性研究,纳入2014至2016年印度Manipal综合癌症中心638例乳腺癌,WFO于2016年提供相同病例的治疗推荐,对不一致病例由肿瘤委员会2016年盲法二次复核。

主要发现

  • WFO与多学科肿瘤委员会治疗一致率为93%。
  • I期或IV期患者一致性低于II期或III期患者。
  • 与<45岁患者相比,除55-64岁组外,所有年龄组一致性显著下降(P ≤ 0.02;P < 0.001)。
  • 受体状态未发现影响一致性。

临床怎么用

  • WFO可能作为乳腺癌治疗决策的有用工具,尤其在专家资源有限的中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer oncologists are challenged to personalize care with rapidly changing scientific evidence, drug approvals, and treatment guidelines. Artificial intelligence (AI) clinical decision-support systems (CDSSs) have the potential to help address this challenge. We report here the results of examining the level of agreement (concordance) between treatment recommendations made by the AI CDSS Watson for Oncology (WFO) and a multidisciplinary tumor board for breast cancer. PATIENTS AND METHODS: Treatment recommendations were provided for 638 breast cancers between 2014 and 2016 at the Manipal Comprehensive Cancer Center, Bengaluru, India. WFO provided treatment recommendations for the identical cases in 2016. A blinded second review was carried out by the center's tumor board in 2016 for all cases in which there was not agreement, to account for treatments and guidelines not available before 2016. Treatment recommendations were considered concordant if the tumor board recommendations were designated 'recommended' or 'for consideration' by WFO. RESULTS: Treatment concordance between WFO and the multidisciplinary tumor board occurred in 93% of breast cancer cases. Subgroup analysis found that patients with stage I or IV disease were less likely to be concordant than patients with stage II or III disease. Increasing age was found to have a major impact on concordance. Concordance declined significantly (P ≤ 0.02; P < 0.001) in all age groups compared with patients <45 years of age, except for the age group 55-64 years. Receptor status was not found to affect concordance. CONCLUSION: Treatment recommendations made by WFO and the tumor board were highly concordant for breast cancer cases examined. Breast cancer stage and patient age had significant influence on concordance, while receptor status alone did not. This study demonstrates that the AI clinical decision-support system WFO may be a helpful tool for breast cancer treatment decision making, especially at centers where expert breast cancer resources are limited.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Somashekhar SP, Sepúlveda MJ, Puglielli S, et al. Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol. 2018. PMID: 29324970. doi:10.1093/annonc/mdx781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。